Research ArticleResearch

A Comparison of Protein Stability in Prefillable Syringes Made of Glass and Plastic

Lloyd Waxman and Vinod D. Vilivalam
PDA Journal of Pharmaceutical Science and Technology November 2017, 71 (6) 462-477; DOI: https://doi.org/10.5731/pdajpst.2016.007146

References

  1. 1.↵
    1. Carpenter J. F.,
    2. Randolph T. W.,
    3. Jiskoot W.,
    4. Crommelin D. J.,
    5. Middaugh C. R.,
    6. Winter G.,
    7. Fan Y. X.,
    8. Kirshner S.,
    9. Verthelyi D.,
    10. Kozlowski S.,
    11. Clouse K. A.,
    12. Swann P. G.,
    13. Rosenberg A.,
    14. Cherney B.
    Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality. J. Pharm. Sci. 2009, 98 (4), 1201–1205.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Rosenberg A. S.
    Effects of Protein Aggregates: An Immunologic Perspective. AAPS J. 2006, 8 (3), E501–E507.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Purcell R. T.,
    2. Lockey R. F.
    Immunologic Responses to Therapeutic Biologic Agents. J. Investig. Allergol. Clin. Immunol. 2008, 18 (5), 335–342.
    OpenUrlPubMed
  4. 4.↵
    1. Singh S. K.,
    2. Afonina N.,
    3. Awwad M.,
    4. Bechtold-Peters K.,
    5. Blue J. T.,
    6. Chou D.,
    7. Cromwell M.,
    8. Krause H. J.,
    9. Mahler H. C.,
    10. Meyer B. K.,
    11. Narhi L.,
    12. Nesta D. P.,
    13. Spitznagel T.
    An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics. J. Pharm. Sci. 2010, 99 (8), 3302–3321.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Jones L. S.,
    2. Kaufmann A.,
    3. Middaugh C. R.
    Silicone Oil Induced Aggregation of Proteins. J. Pharm. Sci. 2005, 94 (4), 918–927.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Thirumangalathu R.,
    2. Krishnan S.,
    3. Ricci M. S.,
    4. Brems D. N.,
    5. Randolph T. W.,
    6. Carpenter J. F.
    Silicone Oil- and Agitation-Induced Aggregation of a Monoclonal Antibody in Aqueous Solution. J. Pharm. Sci. 2009, 98 (9), 3167–3181.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Felsovalyi F.,
    2. Janvier S.,
    3. Jouffray S.,
    4. Soukiassian H.,
    5. Mangiagalli P.
    Silicone-Oil-Based Subvisible Particles: Their Detection, Interactions, and Regulation in Prefilled Container Closure Systems for Biopharmaceuticals. J. Pharm. Sci. 2012, 101 (12), 4569–4583.
    OpenUrlPubMed
  8. 8.↵
    1. Gerhardt A.,
    2. McGraw N. R.,
    3. Schwartz D. K.,
    4. Bee J. S.,
    5. Carpenter J. F.,
    6. Randolph T. W.
    Protein Aggregation and Particle Formation in Prefilled Glass Syringes. J. Pharm. Sci. 2014, 103 (6), 1601–1612.
    OpenUrl
  9. 9.↵
    1. Liu W.,
    2. Swift R.,
    3. Torraca G.,
    4. Nashed-Samuel Y.,
    5. Wen Z.-Q.,
    6. Jiang Y.,
    7. Vance A.,
    8. Mire-Sluis A.,
    9. Freund E.,
    10. Davis J.,
    11. Narhi L.
    Root Cause Analysis of Tungsten-Induced Protein Aggregation in Pre-filled Syringes. PDA J. Pharm. Sci. Technol. 2010, 64 (1), 11–19.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Bee J. S.,
    2. Nelson. S. A.,
    3. Freund E.,
    4. Carpenter J. F.,
    5. Randolph T. W.
    Precipitation of a Monoclonal Antibody by Soluble Tungsten. J. Pharm. Sci. 2009, 98 (9), 3290–3301.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Jiang Y.,
    2. Nashed-Samuel Y.,
    3. Li C.,
    4. Liu W.,
    5. Pollastrini J.,
    6. Mallard D.,
    7. Wen Z.-Q.,
    8. Fujimori K.,
    9. Pallitto M.,
    10. Donahue L.,
    11. Chu G.,
    12. Torraca G.,
    13. Vance A.,
    14. Mire-Sluis T.,
    15. Freund E.,
    16. Davis J.,
    17. Narhi L.
    Tungsten-induced protein aggregation: solution behavior. J. Pharm. Sci. 2009, 98 (12), 4695–4710.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Liu D.,
    2. Nashed-Samuel Y.,
    3. Bondarenko P. V.,
    4. Brems D. N.,
    5. Ren D.
    Interactions between Therapeutic Proteins and Acrylic Acid Leachable. PDA J. Pharm. Sci. Technol. 2012, 66 (1), 12–19.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Shin J. U.,
    2. Park J. L.,
    3. Liu C.,
    4. He J.,
    5. Kim S. C.
    Chemical Structure and Physical Properties of Cyclic Olefin Copolymers. Pure Appl. Chem. 2005, 77 (5), 801–814.
    OpenUrl
  14. 14.↵
    1. Nema S.,
    2. Ludwig J. D.
    1. Vilivalam V. V.,
    2. DeGrazio F. L.
    Plastic Packaging for Farenteral Drug Delivery. In Pharmaceutical Dosage Forms: Parenteral Medications, Nema S., Ludwig J. D., Eds.; Informa Healthcare: New York, 2010; Volume 1.
  15. 15.↵
    1. Yoshino K.,
    2. Nakamura K.,
    3. Yamashita A.,
    4. Abe Y.,
    5. Iwasaki I.,
    6. Kanazuma Y.,
    7. Funatsu K.,
    8. Yoshimoto T.,
    9. Suzuki S.
    Functional Evaluation and Characterization of a Newly Developed Silicone Oil–Free Prefillable Syringe System. J. Pharm. Sci. 2014, 103 (5), 1520–1528.
    OpenUrlPubMed
  16. 16.↵
    1. Kamerzell T. J.,
    2. Li M.,
    3. Arora S.,
    4. Ji J. A.,
    5. Wang Y. J.
    The Relative Rate of Immunoglobulin Gamma 1 Fragmentation. J. Pharm. Sci. 2011, 100 (4), 1341–1349.
    OpenUrl
  17. 17.↵
    1. Vlasak J.,
    2. Ionescu R.
    Fragmentation of Monoclonal Antibodies. mAbs 2011, 3 (3), 253-263.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Bristol-Myers Squibb. Accessed at http://packageinserts.bms.com/pi/piorencia.pdf. Accessed on January 13, 2012.
  19. 19.↵
    1. Majumdar S.,
    2. Ford B. M.,
    3. Mar K. D.,
    4. Sullivan V. J.,
    5. Ulrich R. G.,
    6. D'Souza A. J. M.
    Evaluation of the Effect of Syringe Surfaces on Protein Formulations. J. Pharm. Sci. 2011, 100 (7), 2563–2573.
    OpenUrlPubMed
  20. 20.↵
    1. Krayukhina E.,
    2. Tsumoto K.,
    3. Uchiyama S.,
    4. Fukui K.
    Effects of Syringe Material and Silicone Oil Lubrication on the Stability of Pharmaceutical Proteins. J. Pharm. Sci. 2015, 104 (2), 527–535.
    OpenUrlPubMed
  21. 21.↵
    1. Weiss W. F. IV.,
    2. Hodgdon T. K.,
    3. Kaler E. W.,
    4. Lenhoff A. M.,
    5. Roberts C. J.
    Nonnative Protein Polymers: Structure, Morphology, and Relation to Nucleation and Growth. Biophys. J. 2007, 93 (12), 4392–4403
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Sluzky V.,
    2. Tamada J. A.,
    3. Klibanov A. M.,
    4. Langer R.
    Kinetics of Insulin Aggregation in Aqueous Solutions upon Agitation in the Presence of Hydrophobic Surfaces. Proc. Natl. Acad. Sci. U. S. A. 1991, 88 (21), 9377–9381.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Luo Q.,
    2. Joubert M. K.,
    3. Stevenson R.,
    4. Ketchem R. R.,
    5. Narhi L. O.,
    6. Wypych J.
    Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress Conditions. J. Biol. Chem. 2011, 286 (28), 25134–25144.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Patel J.,
    2. Kothari R.,
    3. Tunga R.,
    4. Ritter N. M.,
    5. Tunga B. S.
    Stability Considerations for Biopharmaceuticals, Part 1: Overview of Protein and Peptide Degradation Pathways. BioProcess International 2011, 9 (1), 20–31.
    OpenUrl
  25. 25.↵
    1. Puri M.,
    2. Morar-Mitrica S.,
    3. Crotts G.,
    4. Nesta D.
    Evaluating Freeze-Thaw Processes in Biopharmaceutical Development. BioProcess International 2015, 13 (1), 34–45.
    OpenUrl
  26. 26.↵
    1. Labrenz S. R.,
    2. Calmann M. A.,
    3. Heavner G. A.,
    4. Tolman G.
    The Oxidation of Methionine-54 of Epoetinum Alfa Does Not Affect Molecular Structure or Stability, but Does Decrease Biological Activity. PDA J. Pharm. Sci. Technol. 2008, 62 (3), 211–223.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Waterman K. C.,
    2. Adami R. C.,
    3. Alsante K. M.,
    4. Hong J.,
    5. Landis M. S.,
    6. Lombardo F.,
    7. Roberts C. J.
    Stabilization of Pharmaceuticals to Oxidative Degradation. Pharm. Dev. Technol. 2002, 7 (1), 1–32.
    OpenUrlPubMed
  28. 28.↵
    1. Li S.,
    2. Schöeneich C.,
    3. Borchardt R. T.
    Chemical Instability of Protein Pharmaceuticals: Mechanisms of Oxidation and Strategies for Stabilization. Biotechnol. Bioeng. 1995, 48 (5), 490–500.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Kerwin B. A.,
    2. Remmele R. I. Jr..
    Protect from Light: Photodegradation and Protein Biologics. J. Pharm. Sci. 2007, 96 (6), 1468–1479.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Nakamura K.,
    2. Abe Y.,
    3. Kiminami H.,
    4. Yamashita A.,
    5. Iwasaki K.,
    6. Suzuki S.,
    7. Yoshino K.,
    8. Dierick W.,
    9. Constable K.
    A Strategy for the Prevention of Protein Oxidation by Drug Product in Polymer-Based Syringes. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 88–95.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Nakamura K.,
    2. Kiminami H.,
    3. Yamashita A.,
    4. Abe Y.,
    5. Yoshino K.,
    6. Suzuki S.
    Assessment of the Effects of Sterilization Methods on Protein Drug Stability by Elucidating Decomposition Mechanism and Material Analysis. Int. J. Pharm. 2015, 484 (1-2), 51–56.
    OpenUrlPubMed
  32. 32.↵
    1. Basu P.,
    2. Krishnan S.,
    3. Thirumangalathu R.,
    4. Randolph T. W.,
    5. Carpenter J. F.
    IgG1 Aggregation and Particle Formation Induced by Silicone-Water Interfaces on Siliconized Borosilicate Glass Beads: A Model for Siliconized Primary Containers. J. Pharm. Sci. 2013, 102 (3), 852–865.
    OpenUrl
Back to top

In This Issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
A Comparison of Protein Stability in Prefillable Syringes Made of Glass and Plastic
Lloyd Waxman, Vinod D. Vilivalam
PDA Journal of Pharmaceutical Science and Technology Nov 2017, 71 (6) 462-477; DOI: 10.5731/pdajpst.2016.007146
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords